This is the authors' abstract. We don't add key points for this paper.
promoter methylation. These findings may provide a rationale for HDAC1/2-targeting therapy in atherosclerotic heart disease.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: